Considerations for prescribing pharmacotherapy for the treatment of erectile dysfunction

Bakr, Ahmed M.; El-Sakka, Amro A; El‐Sakka, Ahmed I.

doi:10.1080/14656566.2020.1851365

Cited by 6 publications

(2 citation statements)

References 124 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Moreover, sildenafil's viability might be improved with shorter spans on dialysis, potentially because of less high-level penile vascular disease (Viigimaa et al, 2020). Several treatment options exist for patients with erectile dysfunction (ED), among which sildenafil citrate stands out as the first oral therapy demonstrating efficacy across a broad spectrum of etiologies (Bakr et al, 2021) diabetes mellitus, and ischemic heart disease (Pyrgidis et al, 2021a). Sildenafil has consistently shown significant improvements in patient's ability to attain and sustain erections compared to a placebo, offering hope to those with ED regardless of underlying health issues (Sangkum et al, 2021).…”

Section: Discussionmentioning

confidence: 99%

Treatment With Sildenafil Citrate in Renal Transplant Patients With Erectile Dysfunction

REHMAN,

MANAN,

ULLAH

et al. 2024

Biol Clin Sci Res J

View full text Add to dashboard Cite

Erectile dysfunction (ED) is a prevalent and distressing condition among renal transplant patients, often stemming from multifactorial causes such as medication side effects, psychological factors, and vascular complications associated with end-stage renal disease (ESRD) and transplantation. The basic aim of the study is to find the treatment with sildenafil citrate in renal transplant patients with erectile dysfunction (ED). This prospective observational study was conducted at the Institute of Kidney Disease Peshawar from 2017 to 2023. A total of 240 participants were recruited using convenience sampling methods. All male patients aged 18 years or older who had undergone renal transplantation and reported persistent ED for a duration of at least six months post-transplantation. Patients who use nitrate medications, severe cardiovascular disease, and uncontrolled hypertension were excluded from the study. Data were collected from 240 patients. The mean age of the patients was 52 ± 8.01 years and the mean duration of the transplant was 5.1 ± 3.2 years. Almost 70% of patients were suffering from hypertension, 45% from DM, and 30% from CVD. The mean level of serum creatinine was 1.5 ± 0.3 mg/dl and the mean GFR was 60 ± 10mL/min/1.73m². The assessment at baseline revealed an IIEF erectile function score of 12.5, which significantly improved to 20.2 at the 12-week follow-up, indicating a notable enhancement in erectile function among participants. Moreover, the frequency of successful intercourse also exhibited a positive change, with participants reporting an increase from 1-2 times per month at baseline to 3-4 times per month at the 12-week. It is concluded that sildenafil citrate demonstrates significant efficacy in improving erectile function and sexual satisfaction among renal transplant patients with erectile dysfunction.

show abstract

Section: Discussionmentioning

confidence: 99%

Treatment With Sildenafil Citrate in Renal Transplant Patients With Erectile Dysfunction

REHMAN,

MANAN,

ULLAH

et al. 2024

Biol Clin Sci Res J

View full text Add to dashboard Cite

show abstract

“…PDE 5 inhibitors are used as the first-line therapy for ED [ 32 ]. As a popular vasodilator, their usage has been observed to improve penile impotence [ 33 ].…”

Section: Pharmacological Properties Of Papaverinementioning

confidence: 99%

Papaverine: A Miraculous Alkaloid from Opium and Its Multimedicinal Application

et al. 2023

View full text Add to dashboard Cite

The pharmacological actions of benzylisoquinoline alkaloids are quite substantial, and have recently attracted much attention. One of the principle benzylisoquinoline alkaloids has been found in the unripe seed capsules of Papaver somniferum L. Although it lacks analgesic effects and is unrelated to the compounds in the morphine class, it is a peripheral vasodilator and has a direct effect on vessels. It is reported to inhibit the cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP) phosphodiesterase in smooth muscles, and it has been observed to increase intracellular levels of cAMP and cGMP. It induces coronary, cerebral, and pulmonary artery dilatation and helps to lower cerebral vascular resistance and enhance cerebral blood flow. Current pharmacological research has revealed that papaverine demonstrates a variety of biological activities, including activity against erectile dysfunction, postoperative vasospasms, and pulmonary vasoconstriction, as well as antiviral, cardioprotective, anti-inflammatory, anticancer, neuroprotective, and gestational actions. It was recently demonstrated that papaverine has the potential to control SARS-CoV-2 by preventing its cytopathic effect. These experiments were carried out both in vitro and in vivo and require an extensive understanding of the mechanisms of action. With its multiple mechanisms, papaverine can be considered as a natural compound that is used to develop therapeutic drugs. To validate its applications, additional research is required into its precise therapeutic mechanisms as well as its acute and chronic toxicities. Therefore, the goal of this review is to discuss the major studies and reported clinical studies looking into the pharmacological effects of papaverine and the mechanisms of action underneath these effects. Additionally, it is recommended to conduct further research via significant pharmacodynamic and pharmacokinetic studies.

show abstract